Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer
Menée à partir d'échantillons sériques prélevés sur 12 témoins et sur 24 patients atteints d'un adénome ou d'un cancer colorectal de stade IV, puis validée à partir de l'analyse de 179 échantillons tumoraux et de 324 échantillons sériques prélevés sur des témoins ou des patients atteints d'un adénome ou d'un cancer colorectal, cette étude met en évidence l'intérêt de mesurer le niveau d'expression du microARN-1290 pour diagnostiquer précocement un cancer colorectal et établir un pronostic
Background : Circulating microRNAs (miRNAs) are attracting major interest as potential noninvasive biomarkers for colorectal cancer (CRC). This study aimed to identify a novel serum miRNA biomarker for the early detection and/or evaluating prognosis of CRC patients.
Patients and methods : Comprehensive miRNA array analysis was performed using serum samples from patients with colorectal neoplasia and healthy controls. Next, to verify whether the candidate miRNA possessed a secretory potential, we screened miRNA expression levels in culture medium from 2 CRC cell lines, followed by serum analysis from 12 stage IV CRC, 12 adenoma and 12 control subjects. Thereafter, we validated expression of candidate miRNAs in 179 primary CRC tissues, as well as serum samples from an independent cohort of 211 CRCs, 56 adenomas, and 57 control subjects.
Results : Through microarray analysis, we identified significantly higher levels of miRNA-1290 (miR-1290) in serum from patients with colorectal adenomas and cancers. We verified miR-1290 overexpression in serum of CRC patients in a training cohort. In the validation cohort, serum miR-1290 levels were significantly upregulated in patients with colorectal adenomas (P<0.0001) and cancers (P<0.0001). Serum miR-1290 levels could robustly distinguish adenoma (area under the curve [AUC]=0.718) and CRC patients (AUC=0.830) from normal subjects. High miR-1290 expression in serum and tissue was significantly associated with tumor aggressiveness and poor prognosis. Moreover, serum miR-1290 levels were an independent prognostic factor (hazard ratio=4.51; 95% confidence interval=1.23-23.69; P=0.0096) and an independent predictor for tumor recurrence (hazard ratio=3.92; 95% confidence interval=1.11-25.14; P=0.032) in CRC.
Conclusions : Serum miR-1290 is a novel biomarker for early detection, recurrence and prognosis in CRC.
Annals of Oncology , résumé, 2016